Merck & Co., Inc. Earnings: What to Expect

The pharma giant is still seeing sluggish sales, but can Merck earnings move forward? Find out here.

Feb 3, 2014 at 11:20PM

Merck (NYSE:MRK) will release its quarterly report on Wednesday, and investors expect to see mixed results from the pharmaceutical giant, as profits could rise even as sales decline. That's a similar pattern to what we've seen from Pfizer (NYSE:PFE), Teva Pharmaceutical (NYSE:TEVA), and other pharmaceutical companies, but Merck faces the longer-term challenge of getting both revenue and profits to hit bottom and start growing at a more consistent pace in the future.

Merck remains a colossus in the health-care industry, even as Pfizer, AbbVie (NYSE:ABBV), and some other competitors have made moves to slim down their extensive operations and instead focus on key growth areas. Yet even though it has been slower than its rivals to consider major corporate moves, Merck nevertheless has a lot of potential to make strategic shifts that could unlock the value of some of its business divisions. Let's take an early look at what's been happening with Merck over the past quarter and what we're likely to see in its report.

G
Source: Wikimedia Commons.

Stats on Merck

Analyst EPS Estimate

$0.88

Change From Year-Ago EPS

6%

Revenue Estimate

$11.36 billion

Change From Year-Ago Revenue

(3.2%)

Earnings Beats in Past 4 Quarters

4

Source: Yahoo! Finance.

Which way are Merck earnings headed this quarter?
In recent months, analysts have been a bit less upbeat about Merck earnings prospects, keeping fourth-quarter estimates stable but cutting about 1% from their projections for the full 2014 year. The stock hasn't held back, though, climbing 15% since late October.

Merck's third-quarter earnings told a story that investors in Pfizer and many other branded-pharmaceutical companies can understand all too well. Even though its adjusted net income beat expectations, Merck's sales fell short of what investors wanted to see, as the loss of patent protection on asthma treatment Singulair and weak sales of its diabetes drug Januvia weighed on its overall results. A reduction in GAAP earnings guidance and continuing expectations for a year-over-year revenue drop of about 5% to 6% between 2012 and 2013 weighed on the stock.

Moreover, a big part of Merck's trouble is that just about all of its business segments have been performing poorly. Pharmaceuticals make up about 86% of Merck's total sales, but during the third quarter, revenue fell at its consumer-care and animal-health segments, as well as for its catch-all "other revenues" category. Problems in maintaining focus are a big part of why Pfizer, AbbVie, and other companies have joined the trend toward breaking up big health-care conglomerates rather than trying to maintain a firm grip on a sprawling set of businesses under one roof.

Still, drug development is a key driver of overall results for Merck, and the bulk of Merck's share-price gains over the past quarter came in mid-January, when the drug company said that it began its FDA submission process for its MK-3475 melanoma and cancer therapy. With expectations of completing the application by mid-2014, Merck hopes that the drug will live up to huge potential, with many analysts looking for MK-3475 to treat not only melanoma but also other types of cancer and hit peak sales levels of $3 billion or more. That would go a long way toward replacing lost revenue from Singulair and other patent-cliff losses.

Merck is also working hard to find strategic alliances. The company said just this week that it would invest $2.3 billion in Belgium's Ablynx, a biotech company that could help Merck develop its cancer-fighting pipeline even more quickly. Perhaps more importantly, some believe that Merck might make a deal with Novartis to swap Merck's over-the-counter consumer products business for Novartis' animal-health line. That at least would make Merck a bigger player in animal health while divesting itself of one minor business, even if it wouldn't represent a full solution that Pfizer's and AbbVie's complete spinoffs addressed more efficiently.

In the Merck earnings report, watch for two things: the latest on its drug pipeline, and any news on the corporate restructuring front. Having held out for so long, a decision from Merck to make a major shift in structure could make the stock soar if investors like what they see.

Be smart about life-saving cancer-fighters
Merck is trying to cure cancer, and the best way investors can play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Merck to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers